Please assess the completion status of the following clinical trial:

Trial Title: Angiogenic and EGFR Blockade With Curative Chemoradiation for Advanced Head and Neck Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: EARLY_PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Locally advanced squamous carcinoma of the head and neck (AJCC stages II/IV, M0, and excluding T1N1 and T1N2) undergoing curative intent concurrent chemoradiation.~* Previous treatment of any sort other than a biopsy is not allowed.~* Eligible anatomic sites:~  * oral cavity~ * oropharynx~ * hypopharynx~ * supraglottic~ * glottic larynx~* KPS \> 60~Exclusion Criteria:~* Nasopharynx primary~* History of malignancy other than basal cell skin cancer.~* History of claudication, bleeding, or thromboembolic disorders. Patients receiving heparin or Coumadin therapy are ineligible.~* Primary tumor or lymph node encasement of the carotid artery~* Blood pressure of \>150/100 mmHg~* Unstable angina~* New York Heart Association (NYHA) Grade II or greater congestive heart failure~* History of myocardial infarction within 6 months~* History of stroke within 6 months~* Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to Day 0; anticipation of need for major surgical procedure during the course of the study.~* Minor surgical procedures, fine needle aspirations, or core biopsies within 7 days prior to Day 0~* Pregnant (positive pregnancy test) or lactating~* Urine protein : creatinine ratio ≥ 1.0 at screening~* History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months prior to Day 0~* Serious, non-healing wound, ulcer, or bone fracture~* AST, ALT, or bilirubin \> 1.5 x normal~* PT or PTT \> 1.5 x normal~* Platelets \< 100,000~* WBC \< 2000~* Hgb \< 10~* Creatinine clearance \< 60 mL/hr~* Refusal to provide written informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ChemoRadiotherapy (Type: EXPERIMENTAL): Radiation Therapy concurrent with cisplatin chemotherapy, Avastin and Tarceva

Based on this trial design, predict the completion outcome and termination type (if applicable).